» Articles » PMID: 20082594

Characteristics and Long-term Outcome of Patients with Autoimmune Hepatitis Related to the Initial Treatment Response

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2010 Jan 20
PMID 20082594
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Autoimmune hepatitis (AIH) is a liver disease which, if untreated, may lead to liver cirrhosis and hepatic failure. Limited data exist regarding factors predicting the long-term outcome. The aims of this study were to investigate symptoms at presentation, prognostic features, management and treatment in relation to long-term outcome of AIH.

Material And Methods: A cohort of 473 Swedish patients with AIH was characterized regarding initial symptoms and signs, factors predicting death and future need for liver transplantation. Survival and causes of death were retrieved from Swedish national registers.

Results: At diagnosis, fatigue was a predominant symptom (69%), 47% of the patients were jaundiced and 30% had liver cirrhosis. Another 10% developed cirrhosis during follow-up. Markedly elevated alanine aminotransferase levels at presentation were correlated with a better outcome. A high international normalized ratio (INR) at diagnosis was the only risk factor predicting a need for later liver transplantation. Histological cirrhosis, decompensation and non-response to initial treatment were all factors that correlated with a worse outcome. Overall life expectancy was generally favourable. However, most deaths were liver-related, e.g. liver failure, shock and gastrointestinal bleeding.

Conclusions: Cirrhosis at diagnosis, a non-response to initial immune-suppressive treatment or elevated INR values were associated with worse outcome and a need for later liver transplantation. In contrast, an acute hepatitis-like onset with intact synthetic capacity indicated a good response to treatment and favourable long-term prognosis. Lifetime maintenance therapy is most often required.

Citing Articles

Trends of Costs and Admission Rates Among Patients Admitted With Autoimmune Hepatitis: Analysis of US Hospitals Using the NIS Database.

Lee D, Schuster K, Bahadur A, Schellhammer S, Ponder R, Mitchell-Sparke E J Clin Exp Hepatol. 2023; 14(1):101279.

PMID: 38076380 PMC: 10709195. DOI: 10.1016/j.jceh.2023.08.015.


Characteristics and Long-Term Outcome of 535 Patients with Autoimmune Hepatitis-The 20-Year Experience of a High-Volume Tertiary Center.

Buechter M, Dorn D, Mohlendick B, Siffert W, Baba H, Gerken G J Clin Med. 2023; 12(13).

PMID: 37445225 PMC: 10342368. DOI: 10.3390/jcm12134192.


Genetic Variants Determine Treatment Response in Autoimmune Hepatitis.

Zandanell S, Balcar L, Semmler G, Schirmer A, Leitner I, Rosenstatter L J Pers Med. 2023; 13(3).

PMID: 36983720 PMC: 10052918. DOI: 10.3390/jpm13030540.


Natural history and management of refractory autoimmune hepatitis.

Whitehead B, Kriegermeier A Clin Liver Dis (Hoboken). 2022; 20(4):120-123.

PMID: 36245680 PMC: 9549313. DOI: 10.1002/cld.1231.


Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.

Tana M, Klepper A, Lyden A, Pisco A, Phelps M, McGee B PLoS One. 2022; 17(3):e0264307.

PMID: 35312680 PMC: 8936448. DOI: 10.1371/journal.pone.0264307.